Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling

Diabetes

Volumn 47, Issue 4, 1998, Pages 632-639

  Scrocchi, Louise A ^a   Marshall, Bess A ^b   Cook, Sonya M ^a   Brubaker, Patricia L ^a   Drucker, Daniel J ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; HORMONE RECEPTOR; INSULIN; PROGLUCAGON; PROINSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; HYPERINSULINEMIA; INSULIN RELEASE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ALLELES; ANIMALS; BLOOD GLUCOSE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN; INTESTINES; MALE; MICE; MUTATION; PANCREAS; PEPTIDE FRAGMENTS; PEPTIDES; PROGLUCAGON; PROTEIN PRECURSORS; RADIOIMMUNOASSAY; RECEPTORS, GLUCAGON; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 0031922709     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.4.632     Document Type: Article

References (56)

1. Creutzfeldt W, Ebert R: New developments in the incretin concept. Diabetologia 28:565-573, 1985
2. Fehmann H-C, Goke R, Goke B: Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr Rev 16:390-410, 1995
3. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM: Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98:2440-2445, 1996
4. Ebert R, Unger H, Creutzfeld W: Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 24:440-454, 1983
5. Jia X, Brown JC, Ma P, Pederson RA, McIntosh CHS: Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am J Physiol Endocrinol Metab 268:E645-E651, 1995
6. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52, 1986
7. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438, 1987
8. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
9. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii:1300-1304, 1987
10. Holst JJ, Orskov C, Nielsen OV, Schwartz TW: Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
11. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and non-diabetic subjects. Diabetes Care 15:270-276, 1992
12. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
13. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905, 1989
14. Ritzel R, Orskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725, 1995
15. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
16. D'alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
17. D'alessio DA, Prigeon RL, Ensinck JW: Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide I. Diabetes 44:1433-1437, 1995
18. Morales M, Lopez-Delgado MI, Alcantara A, Luque MA, Clemente F, Marquez L, Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarrillo ML, Valverde I: Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 46:1264-1269, 1997
19. Thorens B: Expression cloning of the pancreatic β cell receptor for the glucoincretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645, 1992
20. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin -4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
21. Raufman J-P: Bioactive peptides from lizard venoms. Regul Pept 61:1-18, 1996
22. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
23. D'alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:135-138, 1996
24. Kolligs F, Fehmann H-C, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19, 1995
25. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet D, Froguel P, Thorens B: Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208, 1995
26. Wheeler MB, Gelling RW, McIntosh CHS, Georgiou J, Brown JC, Pederson RA: Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signalling properties. Endocrinology 136:4629-4639, 1995
27. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2:1254-1258, 1996
28. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
29. Thiele TE, Van Dyk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein H, Seeley RJ: Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. Am J Physiol 272:R726-R730, 1997
30. Tang-Christensen M, Larsen PJ, Goke R, Fink Jensen A, Jessop DS, Moller M, Sheikh SP: Central administration of GLP-1(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856, 1996
31. Willms B, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1 )-(7-36)amide in type 2 (non-insulin dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
32. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K: Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124:1768-1773, 1989
33. Freyse E-J, Becher T, El-Hag O, Knospe S, Goke B, Fischer U: Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 46:824-828, 1997
34. Chomczynski P, Sacchi N: Single-step method of RNA isolation by add guanidinium thiocyanate-phenol-chloroform extraction. Anal Chem 162:156-159, 1987
35. Drucker DJ, Campos R, Reynolds R, Stobie K, Brubaker PL: The rat glucagon gene is regulated by a cyclic AMP-dependent pathway in pancreatic islet cells. Endocrinology 128:394-400, 1991
36. Brubaker PL, Lee YC, Drucker DJ: Alterations in proglucagon processing and inhibition of proglucagon gene expression in glucagon-SV40 T antigen transgenic mice. J Biol Chem 267:20728-20733, 1992
37. Dhanvantari S, Seidah NG, Brubaker PL: Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342-355, 1996
38. Brubaker PL, So DCY, Drucker DJ: Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. Endocrinology 124:3003-3009, 1989
39. Wang W, Hansen PA, Marshall BA, Holloszy JO, Mueckler MM: Insulin unmasks a C-terminal GLUT4 epitope and increases glucose transport across T-tubules in skeletal muscle. J Cell Biol 135:1-16, 1996
40. Marshall BA, Mueckler MM: Differential effects of GLUT-1 or GLUT-4 over-expression on insulin-responsiveness in transgenic mice. Am J Physiol 267:E738-E744, 1994
41. Fehmann H-C, Habener JF: Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130:159-166, 1992
42. Nauck MA, Wollschlager D, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-l[7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
43. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
44. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F: Expression and functional activity of glucagon, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257-261, 1996
45. Heller RS, Aponte GW: Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36)amide. Am J Physiol 269:G852-G860, 1995
46. Heller RS, Kieffer TJ, Habener JF: Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785-791, 1997
47. Yamato E, Noma Y, Tahara Y, Ikegami H, Yamamoto Y, Cha T, Yoneda H, Ogihara T, Ohboshi C, Hirota M, Shima K: Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. Biochem Biophys Res Commun 167:431-437, 1990
48. Campos RV, Lee YC, Drucker DJ: Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156-2164, 1994
49. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137:2968-2978, 1996
50. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075, 1994
51. Miki H, Namba M, Nishimura T, Mineo I, Matsumura T, Miyagawa J, Nakajima H, Kuwajima M, Hanafusa T, Matsuzawa Y: Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta 1312:132-136, 1996
52. Villanueva-Penacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-l(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
53. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarillo ML: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316, 1994
54. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
55. Nauck MA, Kleine N, Orskov C, Hoist JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
56. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes 45:1524-1530, 1996